Bliss GVS Pharma Share Price

470.0018.11 (4.01%)

Live
As On: 17 Jun, 2026, 10:21 AM IST
As On: 17 Jun, 2026, 10:21 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	456.00
High	473.00
Low	453.00
Prev Close	451.90
Volume	7,79,357
VWAP(₹)	467.23

Share Price	Value
Today/Current/Last	470.00470.65
Previous Day	451.90453.35

Bliss GVS Pharma Share Recommendations

Recent Recos

Target₹214
OrganizationIndependent Analyst
BUY

Target₹220
OrganizationIndependent Analyst
BUY

View all Stock Recommendations

News & Analysis

Positive Breakout: These 10 stocks cross above their 200 DMAs
News
Market Trading Guide: Aeroflex Industries, Bliss GVS Pharma are stock recommendations for Friday
News
Over half of 46 smallcap stocks with double-digit weekly returns, hit fresh 52-week highs
News
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
Announcements

View all Bliss GVS Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	268.15	236.71	264.58	242.92	210.05
Total Income Growth (%)	13.29	-10.53	8.91	15.65	-6.93
Total Expenses	221.20	194.33	220.90	174.34	184.94
Total Expenses Growth (%)	13.83	-12.03	26.71	-5.73	-1.72
EBIT	46.96	42.38	43.67	68.58	25.12
EBIT Growth (%)	10.80	-2.96	-36.32	173.04	-33.02
Profit after Tax (PAT)	35.58	23.27	27.25	43.04	15.54
PAT Growth (%)	52.91	-14.62	-36.68	176.97	-34.72
EBIT Margin (%)	17.51	17.90	16.51	28.23	11.96
Net Profit Margin (%)	13.27	9.83	10.30	17.72	7.40
Basic EPS (₹)	3.37	2.20	2.58	4.08	1.47

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	220.84	174.91	216.07	173.96	165.36
Total Income Growth (%)	26.26	-19.05	24.21	5.20	-13.54
Total Expenses	174.87	148.15	179.90	138.28	149.71
Total Expenses Growth (%)	18.04	-17.65	30.10	-7.63	-6.91
EBIT	45.97	26.77	36.17	35.68	15.66
EBIT Growth (%)	71.73	-26.00	1.39	127.86	-48.56
Profit after Tax (PAT)	32.42	18.61	24.79	21.05	11.45
PAT Growth (%)	74.25	-24.95	17.76	83.83	-45.60
EBIT Margin (%)	20.81	15.30	16.74	20.51	9.47
Net Profit Margin (%)	14.68	10.64	11.47	12.10	6.93
Basic EPS (₹)	3.06	1.76	2.35	2.00	1.08

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	1,000.64	846.22	798.98	769.37	778.95
Total Revenue Growth (%)	18.25	5.91	3.85	-1.23	30.38
Total Expenses	808.57	720.58	652.91	663.30	651.19
Total Expenses Growth (%)	12.21	10.36	-1.57	1.86	32.01
Profit after Tax (PAT)	129.13	84.30	75.45	70.86	15.04
PAT Growth (%)	53.18	11.72	6.49	371.13	-78.04
Operating Profit Margin (%)	22.01	16.51	19.86	15.49	17.72
Net Profit Margin (%)	13.92	10.41	9.79	9.42	2.01
Basic EPS (₹)	12.23	8.02	7.23	6.83	1.46

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	773.53	703.42	638.96	649.11	668.98
Total Revenue Growth (%)	9.97	10.09	-1.56	-2.97	38.45
Total Expenses	637.91	609.25	527.62	533.41	545.33
Total Expenses Growth (%)	4.70	15.47	-1.09	-2.19	39.11
Profit after Tax (PAT)	96.87	68.97	50.64	85.48	92.66
PAT Growth (%)	40.46	36.18	-40.75	-7.75	37.28
Operating Profit Margin (%)	20.10	15.10	19.34	21.01	20.11
Net Profit Margin (%)	13.27	10.33	8.36	14.28	14.56
Basic EPS (₹)	9.17	6.56	4.85	8.23	8.97

All figures in Rs Cr, unless mentioned otherwise

Insights

Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 18.25% outperformed its 3 year CAGR of 9.06%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 1.3% of its operating revenues towards interest expenses and 14.72% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,492.41	1,300.84	1,213.87	1,156.85	1,108.75
Total Assets Growth (%)	14.73	7.16	4.93	4.34	2.97
Total Liabilities	260.65	208.99	210.89	239.43	262.28
Total Liabilities Growth (%)	24.72	-0.90	-11.92	-8.71	5.39
Total Equity	1,231.76	1,091.85	1,002.98	917.42	846.46
Total Equity Growth (%)	12.81	8.86	9.33	8.38	2.24
Current Ratio (x)	4.02	4.81	5.08	3.61	3.33
Total Debt to Equity (x)	0.00	0.07	0.09	0.11	0.13
Contingent Liabilities	0.00	58.85	56.89	11.59	22.70

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	1,344.18	1,219.70	1,152.55	1,139.69	1,079.96
Total Assets Growth (%)	10.21	5.83	1.13	5.53	14.21
Total Liabilities	188.99	161.06	164.11	202.69	228.53
Total Liabilities Growth (%)	17.34	-1.86	-19.03	-11.31	20.30
Total Equity	1,155.19	1,058.63	988.44	937.00	851.43
Total Equity Growth (%)	9.12	7.10	5.49	10.05	12.68
Current Ratio (x)	4.90	6.16	6.59	4.76	4.10
Total Debt to Equity (x)	0.00	0.05	0.07	0.08	0.10
Contingent Liabilities	0.00	58.52	55.82	10.09	21.81

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	138.72	105.91	152.45	34.31	135.48
Net Cash used in Investing Activities	-38.28	-75.44	-132.82	-7.75	-92.98
Net Cash flow from Financing Activities	-89.21	-30.34	-20.89	-24.94	-23.73
Net Cash Flow	11.32	0.23	-1.42	3.02	8.85
Closing Cash & Cash Equivalent	35.14	23.82	23.59	25.01	21.99
Closing Cash & Cash Equivalent Growth (%)	47.55	0.96	-5.66	13.73	67.40
Total Debt/ CFO (x)	0.02	0.67	0.58	2.86	0.77

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	123.16	97.21	125.92	43.81	114.05
Net Cash used in Investing Activities	-51.40	-77.73	-109.59	-12.97	-92.28
Net Cash flow from Financing Activities	-75.37	-26.71	-20.76	-26.05	-12.62
Net Cash Flow	-3.52	-7.23	-4.43	4.79	9.14
Closing Cash & Cash Equivalent	3.33	6.95	14.17	18.60	13.82
Closing Cash & Cash Equivalent Growth (%)	-52.04	-50.98	-23.80	34.65	195.77
Total Debt/ CFO (x)	0.00	0.52	0.52	1.76	0.75

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 38.28 cr for investing activities which is an YoY decrease of 49.26%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	10.82	8.02	7.80	8.01	1.83
Return on Capital Employed (%)	16.23	11.84	14.51	12.08	15.13
Return on Assets (%)	8.65	6.48	6.21	6.12	1.35
Interest Coverage Ratio (x)	19.79	20.10	25.95	13.04	31.60
Asset Turnover Ratio (x)	0.66	0.64	0.65	0.53	0.59
Price to Earnings (x)	17.67	14.71	15.65	10.48	53.19
Price to Book (x)	1.91	1.18	1.22	0.84	0.97
EV/EBITDA (x)	9.07	6.97	6.06	5.70	5.03
EBITDA Margin (%)	25.62	20.15	23.28	17.97	20.04

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	8.38	6.51	5.12	9.12	10.88
Return on Capital Employed (%)	12.48	9.20	11.31	12.74	14.42
Return on Assets (%)	7.20	5.65	4.39	7.50	8.58
Interest Coverage Ratio (x)	15.99	19.41	24.23	14.01	32.80
Asset Turnover Ratio (x)	0.57	0.56	0.53	0.54	0.63
Price to Earnings (x)	23.58	17.99	23.31	8.69	8.61
Price to Book (x)	1.97	1.17	1.19	0.79	0.94
EV/EBITDA (x)	12.21	8.75	7.65	5.21	5.17
EBITDA Margin (%)	24.35	19.15	23.23	23.55	22.28

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Bliss GVS Pharma	38.47	4.03	10.82	16.23	8.65	9.06	22.01	14.53	12.23	4.02	0.00	0.02
Aarti Pharmalabs	31.64	2.78	8.22	10.79	5.01	-2.05	15.09	9.16	19.27	1.49	0.32	2.62
Senores Pharmaceuticals Ltd.	50.61	6.05	12.35	15.60	7.19	156.76	29.10	19.21	26.39	1.92	0.35	5.27
Innova Captab	39.14	5.06	12.91	15.27	7.66	20.29	12.58	8.64	24.63	1.87	0.31	2.94
Orchid Pharma	258.41	4.08	1.59	2.50	1.07	7.22	5.03	2.61	4.05	2.45	0.28	3.53
Add More

Annual Ratios (%)

Choose from Peers

Zota Healthcare
Gujarat Themis
RPG Life Sci
Gufic BioSci
IOL Chemicals

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Bliss GVS Pharma Stock Performance	4.01	62.40	81.60	110.52	286.70	543.39	332.18
Aarti Pharmalabs Stock Performance	1.93	-9.40	-7.79	-6.74	-25.53	84.84	0.00
Senores Pharmaceuticals Ltd. Stock Performance	3.12	35.80	44.74	59.99	151.80	0.00	0.00
Innova Captab Stock Performance	-0.57	9.96	32.49	43.20	8.63	0.00	0.00
Orchid Pharma Stock Performance	-1.65	43.33	85.80	54.29	39.70	143.14	-30.45
Add More

Category	No. of Shares	Percentage	% Change QoQ
Promoters	3,74,04,297	35.36 %	0.00
Pledge	0	0.00 %	0.00
FII	1,10,53,579	10.45 %	-4.09
DII	53,32,920	5.04 %	-0.74
MF	2,829	0.00 %	0.00
Others	5,19,98,176	49.15 %	4.82

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	35.36	35.36	35.39	35.44
Pledge	0.00	0.00	0.00	0.00
FII	10.45	14.54	13.27	12.65
DII	5.04	5.78	5.98	6.54
Mutual Funds	0.00	0.00	0.00	0.00
Others	49.15	44.32	45.36	45.37

Mutual Funds Ownership

MF Ownership as on 31 May 2026

Union Active Momentum Direct-G
Equity: Thematic
- 14.77
  Amount Invested (in Cr.)
- 3.11%
  % of AUM
- 182.95
  % Change (MoM basis)
Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.08
  Amount Invested (in Cr.)
- 0.19%
  % of AUM
- -9.46
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.04
  Amount Invested (in Cr.)
- 0.19%
  % of AUM
- 6.74
  % Change (MoM basis)

View all Mutual Fund Schemes

Corporate Actions

Recent
General Meeting
-
May 12, 2026
Final
100%
May 12, 2026
Board Meeting
Audited Results & Final Dividend
May 05, 2026

Board Meetings

Announced on	Meeting on
May 05, 2026	May 12, 2026
Audited Results & Final Dividend
Feb 03, 2026	Feb 10, 2026
Quarterly Results & Interim Dividend
Oct 29, 2025	Nov 06, 2025
Quarterly Results
Jul 22, 2025	Jul 29, 2025
Quarterly Results
May 05, 2025	May 12, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
Feb 10, 2026 Feb 18, 2026 50%
May 12, 2025 Jul 24, 2025 50%
May 03, 2024 Jul 18, 2024 50%
May 11, 2023 Jul 12, 2023 50%
May 12, 2026 - 100%
Bonus
Announced on Ex-Date
Jul 29, 2008 Sep 26, 2008
Bonus Ratio: 3 share(s) for every 5 shares held
Jul 25, 2005 Sep 28, 2005
Bonus Ratio: 2 share(s) for every 5 shares held
Splits
Announced on Ex-Date
Jan 18, 2008 Mar 11, 2008
Split: Old FV10.0| New FV:1.0
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
May 12, 2026 Jul 15, 2026
-
Apr 09, 2026 May 12, 2026
-
Dec 30, 2025 Feb 01, 2026
-
May 13, 2025 Jun 13, 2025
-
May 12, 2025 Jul 31, 2025
-

Announced on	Ex-Date	Dividend%
Feb 10, 2026	Feb 18, 2026	50%
May 12, 2025	Jul 24, 2025	50%
May 03, 2024	Jul 18, 2024	50%
May 11, 2023	Jul 12, 2023	50%
May 12, 2026	-	100%

Announced on	Ex-Date
Jul 29, 2008	Sep 26, 2008
Bonus Ratio: 3 share(s) for every 5 shares held
Jul 25, 2005	Sep 28, 2005
Bonus Ratio: 2 share(s) for every 5 shares held

Announced on	Ex-Date
Jan 18, 2008	Mar 11, 2008
Split: Old FV10.0\| New FV:1.0

Announced on	Meeting on
May 12, 2026	Jul 15, 2026
-
Apr 09, 2026	May 12, 2026
-
Dec 30, 2025	Feb 01, 2026
-
May 13, 2025	Jun 13, 2025
-
May 12, 2025	Jul 31, 2025
-

About Bliss GVS Pharma

Bliss GVS Pharma Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 4,780.60 Crore) operating in Pharmaceuticals sector.

Bliss GVS Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Export Incentives for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 268.15 Crore, up 13.29 % from last quarter Total Income of Rs 236.71 Crore and up 27.66 % from last year same quarter Total Income of Rs 210.05 Crore. Company has reported net profit after tax of Rs 37.00 Crore in latest quarter.

The company’s top management includes Mr.Nandkumar K Chodankar, Mr.Gagan Harsh Sharma, Mrs.Shruti Vishal Rao, Dr.Vibha Gagan Sharma, Mr.Santosh L Parab, Ms.Shilpa Bhatia, Mr.Deepak B Sawant, Ms.Aditi Bhatt. Company has Kalyaniwalla & Mistry LLP as its auditors. As on 31-03-2026, the company has a total of 10.58 Crore shares outstanding.

Bliss GVS Pharma Share Price Today is Rs. 470.00. On previous day, the Bliss GVS Pharma Share Price (NSE) closed at Rs. 439.55, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 35.36% of the stake in Bliss GVS Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Bliss GVS Pharma stocks was 10.45% as compared to 14.54% in Dec 2025 with decrease of 4.09%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 5.04% as compared to 5.78% in Dec 2025 with decrease of 0.74%. Out of the total DII holdings in Bliss GVS Pharma shares 0.0% was held by mutual funds. The rest including public held is 49.15%. Bliss GVS Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Bliss GVS Pharma Dividend: Ever since 1984, Bliss GVS Pharma dividends has been paid out around 31 times. As on 17 Jun, 2026, 10:21 AM IST, The overall dividend yield for Bliss GVS Pharma stands at 0.33%. The last dividend paid was on February 18, 2026 (Rs. 0.5). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 12.21.

Bliss GVS Pharma Bonus: The most recent bonus issue had been in year September 26, 2008 around 17 years ago at 5 : 3 ratio. The first bonus issue was announced in Jul 2005.

Stock Forecast:
After showing 268.15 Cr. of sales and 13.29% of quarterly net profit, there have been multiple ups and downs in the Bliss GVS Pharma stock prices in the past few weeks. For example, Bliss GVS Pharma stock price on 9th of June 2026 was around Rs. 421.6. Bliss GVS Pharma share price now stands at an average of Rs. 470.00. Judging by last week's performance, stock is in up trend.

Bliss GVS Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Bliss GVS Pharma share.

Historical Prices and Performance:
Bliss GVS Pharma, incorporated in 1984 is a Small Cap company (with a market cap of Rs. 4780.6) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Bliss GVS Pharma stock was 10.82%, 8.02%, 7.8%, 8.01% and 1.83% respectively.
The Bliss GVS Pharma share gave a 3 year return of 452.11% as compared to Nifty 50 which gave a return of 27.43%.
Bliss GVS Pharma announced 50.0% final dividend on February 18, 2026.

Key Metrics:
PE Ratio of Bliss GVS Pharma is 37.02
Prices/Sales Ratio of Bliss GVS Pharma is 2.46
Price/Book Ratio of Bliss GVS Pharma is 3.88

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Bliss GVS Pharma, major competitors and peers include Aarti Pharmalabs, Senores Pharmaceuticals Ltd., Innova Captab and Orchid Pharma . As of Dec 2025, the dividend yield of Bliss GVS Pharma stands at 0.33% while Aarti Pharmalabs, Senores Pharmaceuticals Ltd., Innova Captab and Orchid Pharma stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 37.02 and 3.88 respectively.

Leadership of Bliss GVS Pharma :
Aditi Bhatt is Co. Secretary & Compl. Officer
Deepak B Sawant is Chief Financial Officer
Nandkumar K Chodankar is Chairman & Ind.Director
Gagan Harsh Sharma is Managing Director
Vibha Gagan Sharma is Whole Time Director
Shruti Vishal Rao is Whole Time Director
Santosh L Parab is Independent Director
Shilpa Bhatia is Independent Woman Director

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE MidSmallCap

Address

102, Hyde Park,Saki Vihar Road,Andheri - East,Mumbai, Maharashtra - 400072

Contact

info@blissgvs.com

http://www.blissgvs.com

PE Ratio(x)	38.42
EPS - TTM(₹)	12.21
MCap(₹ Cr.)	4,961.50
MCap Rank	62
PB Ratio(x)	3.88
Div Yield(%)	0.32
Face Value(₹)	1.00
52W High(₹)	473.00
52W Low(₹)	118.00
MCap/Sales	2.46
Beta(1 Month)	1.25
BV/Share(₹)	116.44

PE Ratio(x)	38.41
EPS - TTM(₹)	12.21
MCap(₹ Cr.)	4,960.44
MCap Rank	62
PB Ratio(x)	3.89
Div Yield(%)	0.32
Face Value(₹)	1.00
52W High(₹)	472.65
52W Low(₹)	118.35
MCap/Sales	2.46
Beta(1 Month)	0.87
BV/Share(₹)	116.44

1 Day	4.01%
1 Month	69.28%
3 Months	123.0%
1 Year	231.36%
3 Years	474.22%
5 Years	324.57%

1 Day	3.81%
1 Month	69.18%
3 Months	123.69%
1 Year	231.56%
3 Years	476.42%
5 Years	325.16%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Bliss GVS Pharma Share Price

Key Metrics